A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers
| Image |  |
|---|---|
| Description | scientific article published on 11 November 2014 |
| Author/s | |
| Publication date | November 11, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |